Condition: Non-valvular Atrial Fibrillation (NVAF) · Sponsor: Lifetech Scientific (Shenzhen) Co., Ltd.
To evaluate the preliminary safety and feasibility of the LAmbreTM II Left Atrial Appendage Occluder and the Occluder Delivery System in patients with non-valvular atrial fibrillation who are at increased risk for stroke and systemic embolism.
This description comes directly from the study's public registry record.
Kent CY So, Professor · 0852-3505-1518 · Scy309@ha.org.hk
Kadir Shemsi, CTM · 0852-9142-6007 · KaDirr@lifetechmed.com
Always discuss trial participation with your own doctor first.
| Prince of Wales Hospital, Chinese University of Hong Kong, HKSAR | Shatin, Hong Kong | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07385599